A 5-Question Quiz on Sarcoma

Article

Do you know the most common site of metastasis in soft-tissue sarcoma? Or which histologies are most sensitive to chemotherapy? Answer these questions and more.

Question 1:

Answer and Question 2 on Next Page »

The correct answer is D. Rhabdomyosarcoma

Question 2:

Answer and Question 3 on Next Page »

The correct answer is B. Preoperative radiotherapy may be associated with better local control and increased risk of acute wound complications

Question 3:

Answer and Question 4 on Next Page »

The correct answer is C. 45 to 55 years

Question 4:

Answer and Question 5 on Next Page »

The correct answer is B. Lymphadenectomy is required given the high likelihood of nodal metastasis

Question 5:

Answer on Next Page »

The correct answer is A. Lung

 

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content
The VIOLETTE trial, which used OBT-fusion technology for patients with focal ablation of the prostate by microwave needles, released interim results.

VIOLETTE Trial Shows Precise Planning in Prostate Cancer Microwave Ablation

Tim Cortese
November 22nd 2024
Article

The VIOLETTE trial, which used OBT-fusion technology for patients with focal ablation of the prostate by microwave needles, released interim results.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MS
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

FDA Updates Fludarabine Phosphate Labeling in Chronic Lymphocytic Leukemia

Russ Conroy
November 21st 2024
Article

The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

ONCOLOGY Staff
November 21st 2024
Article

Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.

Results from the HERIZON-BTC-01 trial led to the approval of zanidatamab for patients with metastatic HER2-positive biliary tract cancer.

FDA OKs Zanidatamab Injection for Metastatic HER2+ Biliary Tract Cancer

Ariana Pelosci
November 21st 2024
Article

Results from the HERIZON-BTC-01 trial led to the approval of zanidatamab for patients with metastatic HER2-positive biliary tract cancer.